Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor Appoints Bart Cornelissen as Chief Financial Officer

Business Wire 9 days ago

Xencor to Present at Upcoming Investor Conferences

Business Wire February 28, 2024

Xencor Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 27, 2024

Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update

Business Wire February 20, 2024

Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2024

Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy

Business Wire January 2, 2024

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Business Wire November 21, 2023

Xencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million

Business Wire November 7, 2023

Xencor Reports Third Quarter 2023 Financial Results

Business Wire November 7, 2023

Xencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting

Business Wire November 3, 2023

Xencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023

Business Wire October 31, 2023

Xencor Announces Planned Retirement of Chief Financial Officer John Kuch

Business Wire October 26, 2023

Xencor to Present Multiple Posters at the SITC Annual Meeting

Business Wire September 27, 2023

Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

Business Wire September 19, 2023

Xencor Reports Second Quarter 2023 Financial Results

Business Wire August 3, 2023

Xencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023

Business Wire July 27, 2023

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Business Wire May 30, 2023

Xencor Reports First Quarter 2023 Financial Results

Business Wire May 8, 2023

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

Business Wire May 1, 2023

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

Business Wire April 26, 2023